PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.

Documents similaires

• Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.
  par: Campbell, A, et autres
  Publié: (2010)
• Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
  par: Ait-Tahar, K, et autres
  Publié: (2009)
• PASD1 is a potential multiple myeloma-associated antigen.
  par: Sahota, S, et autres
  Publié: (2006)
• DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
  par: Joseph-Pietras, D, et autres
  Publié: (2010)
• Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
  par: Ait-Tahar, K, et autres
  Publié: (2009)